Pliant Therapeutics, Inc.
NASDAQ:PLRX
12.63 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Pliant Therapeutics, Inc. |
Symbool | PLRX |
Munteenheid | USD |
Prijs | 12.63 |
Beurswaarde | 768,580,968 |
Dividendpercentage | 0% |
52-weken bereik | 10.22 - 18.92 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. |
Website | https://pliantrx.com |
An error occurred while fetching data.
Over Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)